UMGCC requests developmental funds amounting to $260,000, or 9 percent of the total direct costs of its budget. These funds are essential for UMGCC to: ? Pilot projects for Developing Pain Studies Program ($50,000) ? Provide funds to support the establishment of three new developing shared sen/ices ($60,000) ? Fund five new pilot projects for Shared Services annually ($50,000) ? Conduct recruiting for epidemiology ($100,000) Developmental funds will be necessary for UMGCC's leadership to recruit faculty in high-priority areas established by the strategic planning process. In addition, the promotion of Interdisciplinary research will require seed money for pilot grant support in areas that bring investigators of different disciplines together and utilize UMGCC's shared services. Finally, core grant support will be necessary for further establishing essential shared services, such as imaging, molecular pathology, and high-throughput screening. Developmental funds from the P30 Grant will continue to be leveraged by additional funds from Maryland's CRFP and the American Cancer Society (ACS) over the next 5 years. Allocation of developmental funds will be through (a) the strategic-planning process internal to UMGCC, with peer review and approval of the UMGCC Research Council;and (b) recruitment in predefined areas that meet the criteria established by senior leadership. The 2008 NCI Site Visit Report gave this section an Excellent to Very Good rating. NCI thought that requests were well justified and the monies would augment the substantial investment that UMGCC had made in developing programs and shared services. NCI noted the description of the planned usage of these combined investments lacked adequate focus and prioritization of two developing programs and four additional shared services.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA134274-04
Application #
8340234
Study Section
Subcommittee G - Education (NCI)
Project Start
2011-08-24
Project End
2016-07-31
Budget Start
2011-08-24
Budget End
2012-07-31
Support Year
4
Fiscal Year
2011
Total Cost
$123,095
Indirect Cost
Name
University of Maryland Baltimore
Department
Type
DUNS #
188435911
City
Baltimore
State
MD
Country
United States
Zip Code
21201
Connolly, Sean; Quasi-Woode, Devona; Waldron, Laura et al. (2018) Calcineurin Regulatory Subunit Calcium-Binding Domains Differentially Contribute to Calcineurin Signaling in Saccharomyces cerevisiae. Genetics 209:801-813
Pauza, C David; Liou, Mei-Ling; Lahusen, Tyler et al. (2018) Gamma Delta T Cell Therapy for Cancer: It Is Good to be Local. Front Immunol 9:1305
Wang, Lei; Felts, Sara J; Van Keulen, Virginia P et al. (2018) Integrative Genome-Wide Analysis of Long Noncoding RNAs in Diverse Immune Cell Types of Melanoma Patients. Cancer Res 78:4411-4423
McCusker, Michael G; El Chaer, Firas; Duffy, Alison et al. (2018) Combination of Blinatumomab and Vincristine Sulfate Liposome Injection for Treatment of Relapsed Philadelphia Chromosome Positive B-cell Acute Lymphoblastic Leukemia. Am J Leuk Res 2:
Wang, Junxiang; Zhao, Liang; Ye, Yanfang et al. (2018) Adverse event detection by integrating twitter data and VAERS. J Biomed Semantics 9:19
Furusawa, Aki; Reiser, John; Sadashivaiah, Kavitha et al. (2018) Eomesodermin Increases Survival and IL-2 Responsiveness of Tumor-specific CD8+ T Cells in an Adoptive Transfer Model of Cancer Immunotherapy. J Immunother 41:53-63
Nathenson, Michael J; Conley, Anthony P; Sausville, Edward (2018) Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas. Oncologist 23:71-83
Wang, Lei; Felts, Sara J; Van Keulen, Virginia P et al. (2018) Exploring the effect of library preparation on RNA sequencing experiments. Genomics :
Nathenson, Michael J; Barysauskas, Constance M; Nathenson, Robert A et al. (2018) Surgical resection for recurrent retroperitoneal leiomyosarcoma and liposarcoma. World J Surg Oncol 16:203
Sallmyr, Annahita; Tomkinson, Alan E (2018) Repair of DNA double-strand breaks by mammalian alternative end-joining pathways. J Biol Chem 293:10536-10546

Showing the most recent 10 out of 257 publications